Incannex Healthcare Inc. (IXHL)

Market Cap	107.19M +247.2%
Revenue (ttm)	12,000 -86.0%
Net Income	-47.87M
EPS	-0.44
Shares Out	346.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,595,114
Open	0.3100
Previous Close	0.3115
Day's Range	0.3050 - 0.3233
52-Week Range	0.0800 - 2.2500
Beta	2.59
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 13, 2026

About IXHL

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixe...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 12
• Stock Exchange: NASDAQ
• Ticker Symbol: IXHL
• Website: https://www.incannex.com

Financial Performance

In fiscal year 2025, Incannex Healthcare's revenue was $86,000, an increase of 616.67% compared to the previous year's $12,000. Losses were -$46.89 million, 154.0% more than in 2024.